| scholarly article | Q13442814 |
| P50 | author | Jennifer Loftis | Q57513356 |
| P2093 | author name string | Peter Hauser | |
| Muhamad Aly Rifai | |||
| David Indest | |||
| P2860 | cites work | Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction | Q27477533 |
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Prevalence of hepatitis C among psychiatric patients in the public sector. | Q51951423 | ||
| Interferon-?? Treatment of Patients with Hepatitis C | Q58769797 | ||
| Comanagement of Depression and HCV Treatment | Q58769831 | ||
| Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study | Q72991317 | ||
| Prophylactic treatment of depression induced by interferon-alpha | Q73031256 | ||
| Estimating future hepatitis C morbidity, mortality, and costs in the United States | Q73073538 | ||
| National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C | Q73717356 | ||
| Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma | Q73959085 | ||
| Interferon treatment of hepatitis C associated with symptoms of PTSD | Q77422985 | ||
| Alcohol and hepatitis C | Q80530937 | ||
| Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders | Q82766700 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Psychiatric comorbidity among hepatitis C-positive patients | Q30308359 | ||
| Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders | Q30439671 | ||
| Cerebral dysfunction in chronic hepatitis C infection | Q30773516 | ||
| Central nervous system involvement in hepatitis C virus infection | Q30976735 | ||
| Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review | Q33930192 | ||
| Side effects of therapy of hepatitis C and their management | Q34984142 | ||
| Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. | Q35011072 | ||
| New insights into hepatitis C. | Q35045792 | ||
| Viral hepatitis C. | Q35617324 | ||
| Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force | Q35692299 | ||
| Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. | Q35910857 | ||
| The phenomenology and treatment of interferon-induced depression. | Q35920014 | ||
| Cytokines and psychopathology: lessons from interferon-alpha | Q35970243 | ||
| Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. | Q36178177 | ||
| Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care | Q36272273 | ||
| Sertraline treatment of interferon-alfa-induced depressive disorder | Q39425167 | ||
| Limited success of HCV antiviral therapy in United States veterans | Q39591595 | ||
| Approach to the patient with chronic hepatitis C virus infection | Q40582027 | ||
| The epidemiology of psychiatric disorders and the de facto mental health care system | Q41036485 | ||
| Substance abuse and the transmission of hepatitis C among persons with severe mental illness | Q42600268 | ||
| Interferon for hepatitis C patients with psychiatric disorders | Q42989219 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Paroxetine for the prevention of depression induced by high-dose interferon alfa | Q43556890 | ||
| Evidence for a cerebral effect of the hepatitis C virus | Q43674951 | ||
| Surprisingly small effect of antiviral treatment in patients with hepatitis C. | Q43889137 | ||
| Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. | Q43942974 | ||
| Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. | Q44006202 | ||
| Psychiatric disorders among veterans with hepatitis C infection | Q44081498 | ||
| Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. | Q44183496 | ||
| A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. | Q44194141 | ||
| Hepatitis C treatment of veterans with psychiatric illness | Q44239734 | ||
| IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity | Q45115322 | ||
| Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression | Q45227683 | ||
| Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans | Q45333016 | ||
| Approaching treatment for hepatitis C virus infection in substance users | Q45422844 | ||
| Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. | Q46379387 | ||
| The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services | Q50127660 | ||
| A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. | Q50583478 | ||
| Prevalence of hepatitis C in psychiatric institutions. | Q51946930 | ||
| P433 | issue | 6 | |
| P921 | main subject | hepatitis C | Q154869 |
| P304 | page(s) | 508-519 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Current treatment options in gastroenterology | Q27714745 |
| P1476 | title | Psychiatric management of the hepatitis C patient | |
| P478 | volume | 9 |
| Q30540697 | A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment |
| Q35087836 | Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. |
| Q42978310 | Hepatitis C services and individuals with serious mental illness |
| Q26748575 | Hepatitis C virus and neurological damage |
| Q26776387 | Hepatitis C virus as a systemic disease: reaching beyond the liver |
| Q37432112 | Interferon-based hepatitis C treatment in patients with pre-existing severe mental illness and substance use disorders |
| Q36638638 | Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review |
| Q43269486 | Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study |
| Q34743058 | Psychiatric care of the patient with hepatitis C: a review of the literature |
| Q35393471 | Social support and clinical outcomes during antiviral therapy for chronic hepatitis C |
| Q37432877 | The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). |
| Q34962752 | Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders |
Search more.